Feels like another AI pop, then fade.
Anyone else feel weirdly euphoric after this rally? Or is it just the usual post-earnings AI mania?
From a sector lens, this looks like semis and cloud still leading, while broader tech lags. If $NVDA cools, expect SPY to underperform QQQ as growth gets squeezed. Watching AMD and MSFT for balance.
Market feels like a casino today. $QQQ barely budged, yet 523k contracts traded, mostly neutral, and suddenly everyone's calling it a 'big move.' Feels like noise chasing headlines, not conviction.
Not buying the 'big move' hype. Below 50/200-day, thin 0DTE, and that premium looks like thin air. I'm staying underweight QQQ until momentum flips.
Seen this before; options crushes fade fast.
Anyone have the time/price for that 2M volume? Is it premarket, and what's the average order size?
Watching SMCI break out on the AH, then fading the first bid. If it holds above the open and keeps volume, I'll scalp the bounce; otherwise, likely a quick fade into the close.
Impressive numbers, sure, but the market keeps rewarding hype over fundamentals. If SMCI can't show consistent revenue growth and clear differentiation, this kind of volume usually fades fast.
I’m not chasing SELLAS until we see a credible partner timeline. If MRK signals interest, I’ll nibble. Otherwise, I’ll wait for a pullback and buy dips, hedged with puts. Volatility’s fine if it creates value.
Seen this movie with Takeda and AstraZeneca buying smaller players after late-stage wins. But pharma deals take years to close, and regulatory hurdles can derail everything. If Merck does engage, it’ll likely be a staged partnership, not a quick buyout.
Why do we always chase headlines before any deal?
Everyone’s leaning bearish on AMZN after the miss, but I’m seeing a classic capitulation setup: guidance cuts, weak print, yet the stock still trades with some cushion. If sentiment cools further, risk/reward flips.
Seen this movie with Amazon before—revenue growth slows, costs creep up, guidance gets trimmed, and the market whipsaws for weeks. The real test is execution on Prime and AWS. Patience usually pays, but patience has a price.
Feels like Amazon keeps missing the mark on guidance while margins barely budged. Market patience is wearing thin.
I’m not buying the “millions” hype. 0DTE options are brutal with slippage, bid-ask, and volatility. If CELH’s just a proxy, spreads get ugly. Feels like a fat-tail trap.
Interesting backtest, but 0DTE SPY strategies hinge on volatility and liquidity. If CELH reverts, does the edge hold across sessions?
Everyone’s cheering a million-dollar backtest, but 0DTE strategies are brutal in thin sessions. I doubt real-world results look this clean.
Feels like a classic buy-the-dip setup, but I’m uneasy. PAIN is preclinical, AAL’s leverage is real, and the market’s pricing in a miracle. If Phase 1 fails, this could sting.
Rates still high; airline debt makes this risky.
Everyone’s cheering the AAL-PAIN tie-up, but I’m oddly bullish on the underdog. If PAIN’s pipeline actually matures, AAL gets a de-risked asset. Market’s pricing this as a PR stunt; I think it’s a real catalyst.
Is this a buy-the-dip setup, or wait for $300?
Given AMZN’s guidance and the $300 target, how are you sizing the tech/retail sleeve versus cash? Are you trimming growth names and rotating into cash-flowier sectors, or keeping exposure steady until the next catalyst?
Trend looks sideways: higher lows, lower highs, volume hasn’t spiked. Until we see a clean push above $300 with conviction, momentum traders probably stay on the sidelines. Watching relative strength versus MSFT and GOOGL.
